Australia - English - Department of Health (Therapeutic Goods Administration)

servier laboratories (aust) pty ltd - perindopril arginine, quantity: 10 mg; amlodipine besilate, quantity: 13.87 mg - tablet, uncoated - excipient ingredients: magnesium stearate; colloidal anhydrous silica; lactose monohydrate; microcrystalline cellulose - is indicated as substitution therapy for the treatment of hypertension and/or stable coronary heart disease in patients already controlled with separate doses of perindopril and amlodipine, given concurrently at the same dose level. treatment should not be initiated with this combination.

Australia - English - Department of Health (Therapeutic Goods Administration)

servier laboratories (aust) pty ltd - amlodipine besilate, quantity: 6.935 mg; perindopril arginine, quantity: 10 mg - tablet, uncoated - excipient ingredients: colloidal anhydrous silica; magnesium stearate; lactose monohydrate; microcrystalline cellulose - is indicated as substitution therapy for the treatment of hypertension and/or stable coronary heart disease in patients already controlled with separate doses of perindopril and amlodipine, given concurrently at the same dose level. treatment should not be initiated with this combination.

Australia - English - Department of Health (Therapeutic Goods Administration)

servier laboratories (aust) pty ltd - amlodipine besilate, quantity: 13.87 mg; perindopril arginine, quantity: 5 mg - tablet, uncoated - excipient ingredients: colloidal anhydrous silica; magnesium stearate; lactose monohydrate; microcrystalline cellulose - is indicated as substitution therapy for the treatment of hypertension and/or stable coronary heart disease in patients already controlled with separate doses of perindopril and amlodipine, given concurrently at the same dose level. treatment should not be initiated with this combination.

Australia - English - Department of Health (Therapeutic Goods Administration)

servier laboratories (aust) pty ltd - amlodipine besilate, quantity: 6.935 mg; perindopril arginine, quantity: 5 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; magnesium stearate; lactose monohydrate; colloidal anhydrous silica - is indicated as substitution therapy for the treatment of hypertension and/or stable coronary heart disease in patients already controlled with separate doses of perindopril and amlodipine, given concurrently at the same dose level. treatment should not be initiated with this combination.

Australia - English - Department of Health (Therapeutic Goods Administration)

servier laboratories (aust) pty ltd - agomelatine, quantity: 25 mg - tablet, film coated - excipient ingredients: magnesium stearate; povidone; stearic acid; colloidal anhydrous silica; sodium starch glycollate type a; maize starch; lactose monohydrate; propylene glycol; butan-1-ol; ethanol; isopropyl alcohol; shellac; strong ammonia solution; indigo carmine aluminium lake; titanium dioxide; hypromellose; iron oxide yellow; macrogol 6000; glycerol - treatment in adults of: - of major depression (mdd) including prevention of relapse - generalised anxiety disorder (gad)

Australia - English - Department of Health (Therapeutic Goods Administration)

servier laboratories (aust) pty ltd - amlodipine besilate, quantity: 13.87 mg; perindopril arginine, quantity: 10 mg - tablet, uncoated - excipient ingredients: colloidal anhydrous silica; microcrystalline cellulose; lactose monohydrate; magnesium stearate - coveram is indicated as substitution therapy for the treatment of hypertension and/or stable coronary heart disease in patients already controlled with separate doses of perindopril and amlodipine, given concurrently at the same dose level. treatment should not be initiated with this combination.

Australia - English - Department of Health (Therapeutic Goods Administration)

servier laboratories (aust) pty ltd - perindopril arginine, quantity: 10 mg; amlodipine besilate, quantity: 6.935 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; lactose monohydrate; magnesium stearate; colloidal anhydrous silica - coveram is indicated as substitution therapy for the treatment of hypertension and/or stable coronary heart disease in patients already controlled with separate doses of perindopril and amlodipine, given concurrently at the same dose level. treatment should not be initiated with this combination.

Australia - English - Department of Health (Therapeutic Goods Administration)

servier laboratories (aust) pty ltd - amlodipine besilate, quantity: 13.87 mg; perindopril arginine, quantity: 5 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; magnesium stearate; colloidal anhydrous silica; lactose monohydrate - coveram is indicated as substitution therapy for the treatment of hypertension and/or stable coronary heart disease in patients already controlled with separate doses of perindopril and amlodipine, given concurrently at the same dose level. treatment should not be initiated with this combination.

Australia - English - Department of Health (Therapeutic Goods Administration)

servier laboratories (aust) pty ltd - amlodipine besilate, quantity: 6.935 mg; perindopril arginine, quantity: 5 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; lactose monohydrate; magnesium stearate; colloidal anhydrous silica - coveram is indicated as substitution therapy for the treatment of hypertension and/or stable coronary heart disease in patients already controlled with separate doses of perindopril and amlodipine, given concurrently at the same dose level. treatment should not be initiated with this combination.

Australia - English - Department of Health (Therapeutic Goods Administration)

servier laboratories (aust) pty ltd - perindopril erbumine, quantity: 8 mg - tablet, uncoated - excipient ingredients: hydrophobic colloidal silica anhydrous; magnesium stearate; chlorophyllin-copper complex; lactose monohydrate; microcrystalline cellulose - treatment of hypertension. treatment of heart failure. in such patients it is recommended that perindo be given with a diuretic and/or digoxin under close medical supervision. (the safety and efficacy of perindo has not been demonstrated for new york heart association category iv patients). patients with established coronary artery disease (see clinical trials) who are stable on concomitant therapy and have no heart failure to reduce the risk of non-fatal myocardial infarction or cardiac arrest.